SMP0120690
View Pathway
|
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH
Rattus norvegicus
Congenital Lipoid Adrenal Hyperplasia (CLA),also called steroid 20-22 desmolase deficiency and lipoid CAH, is an autosomal recessive disorder and caused by a defective cholesterol side-chain cleavage enzyme. Cholesterol side-chain cleavage enzyme catalyzes the conversion of cholesterol into 20α-Hydroxycholesterol which is also a substrate of cholesterol side-chain cleavage enzyme. This disorder is characterized by a large accumulation of cholesterol in the mitochondrial. Symptoms of the disorder is not clear. Extra glucocorticoid and mineral replacement could be the potential treatments.
|
|
- 11-Dehydrocorticosterone
- 11b,17a,21-Trihydroxypreg-neno...
- 11b,21-Dihydroxy-3,20-oxo-5b-p...
- 11b,21-Dihydroxy-5b-pregnane-3...
- 11b-Hydroxyprogesterone
- 17-Hydroxyprogesterone
- 17a,20a-Dihydroxycholesterol
- 17a,21-Dihydroxy-5b-pregnane-3...
- 17a-Hydroxypregnenolone
- 17α,21-Dihydroxypregnenolone
- 18-Hydroxycorticosterone
- 20a,22b-Dihydroxycholesterol
- 20α-Hydroxycholesterol
- 21-Deoxycortisol
- 21-Hydroxy-5b-pregnane-3,11,20...
- 21-Hydroxypregnenolone
- 22b-Hydroxycholesterol
- 3a,11b,21-Trihydroxy-20-oxo-5b...
- 3a,21-Dihydroxy-5b-pregnane-11...
- 3a-Hydroxy-5b-pregnane-20-one
- 4-Methylpentanal
- 5a-Pregnane-3,20-dione
- Aldosterone
- Cholesterol
- Cortexolone
- Corticosterone
- Cortisol
- Cortisone
- Deoxycorticosterone
- Dihydrocortisol
- Heme
- Hydrogen Ion
- NAD
- NADH
- NADP
- NADPH
- Oxygen
- Pregnenolone
- Progesterone
- Tetrahydrocorticosterone
- Tetrahydrocortisol
- Tetrahydrocortisone
- Water
- (
show all
show less
)
|
|
SMP0120691
View Pathway
|
Cystathionine beta-Synthase Deficiency
Rattus norvegicus
Cystathionine Beta-Synthase Deficiency (CBS Deficiency; Homocystinuria) is an autosomal recessive disease caused by a mutation in the CBS gene which codes for cystathionine beta-synthase. A deficiency in this enzyme results in accumulation of L-cystathionine, homocysteine, and L-homocystine in plasma and urine; and L-methionine and ornithine in plasma. Symptoms include osteoporosis, myopia, fatty-liver, mental retardation, and early death. Treatment includes folic acid, vitamin B6, vitamin B12, and a methionine-restricted diet.
|
|
|
|
SMP0120692
View Pathway
|
Desmosterolosis
Rattus norvegicus
Desmosterolosis is caused by a mutation in the DHCR24 gene, which codes for the enzyme 24-dehydrocholesterol reductase, which catalyzes the reduction of the delta-24 double bond of sterol intermediates. A defect in 24-dehydrocholesterol reductase causes accumulation of desmosterol in plasma. Symptoms include cleft palate, clubfoot, dysmorphism, mental and motor retardation, and speech development.
|
|
|
|
SMP0120693
View Pathway
|
Dihydropyrimidinase Deficiency
Rattus norvegicus
Dihydropyrimidinase Deficiency (DHPA, Dihydropyrimidinuria Deficiency, DPH Deficiency) is an autosomal recessive disease caused by a mutation in the DPYS gene which codes for dihydropyrimidinase. A deficiency in this enzyme results in accumulation of dihydrothymine, dihydrouracil, thymine, and uracil in urine. Symptoms, which present at birth, include metabolic acidosis, difficulty feeding, and seizures.
|
|
|
|
SMP0120694
View Pathway
|
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)
Rattus norvegicus
Dihydropyrimidine Dehydrogenase Deficiency (DHPD; Thymine-uraciluria) is a rare autosomal recessive disorder caused by a mutation in the DPYD gene which codes for dihydropyrimidine dehydrogenase. A deficiency in this enzyme results in accumulation of 5-hydroxymethyluracil, thymine, and uracil in urine. Symptoms include nystagmus, large liver, hypotonia, growth and mental retardation, and seizures.
|
|
|
|
SMP0120695
View Pathway
|
Dimethylglycine Dehydrogenase Deficiency
Rattus norvegicus
Dimethylglycine dehydrogenase deficiency, also called DMGDH deficiency and dimethylglycinuria, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of glycine metabolism caused by a defective DMGDH gene. DMGDH codes for the mitochondrial protein dimethylglycine dehydrogenase which catalyzes the conversion of dimethylglycine into sarcosine. This disorder is characterized by a large accumulation of N,N-dimethylglycine (DMG) and creatinine kinase in serum, and DMG in the urine. Symptoms of the disorder include an unusual fish-like odour and muscle weakness. It is estimated that DMGDH deficiency affects 1 in 1 000 000 individuals.
|
|
|
|
SMP0120696
View Pathway
|
Ethylmalonic Encephalopathy
Rattus norvegicus
Ethylmalonic Encephalopathy (Epema Syndrome; EE) is a rare autosomal recessive disorder caused by a mutation in the ETHE1 gene which codes for protein ETHE1. A deficiency of this protein inhibits proper energy production in mitochondria and a deficiency in cytochrome c oxidase. This results in accumulation of 2-methylbutyrylglycine, N-butyrylglycine, isobutyrylglycine, isovalerylglycine, and methylsuccinic acid in urine. Concentrations of L-carnitine are reduced in plasma. Symptoms, which present at birth, include peripheral neuropathy, seizures, microcephaly, and hypotonia lead to premature death. Treatment includes riboflavin and L-carnitine.
|
|
|
|
SMP0120697
View Pathway
|
Familial Hypercholanemia (FHCA)
Rattus norvegicus
Familial Hypercholanemia can be caused by mutations in the TJP2, BAAT or EPHX1 genes which code for bile acid-CoA:amino acid N-acyltransferase, which plays a part in the metabolism of in bile acids. This enzyme plays a particularly important role in the hepatocytes of the liver. In this region the said enzyme is in part responsible for the catalysis of C24 bile acids (also known as choloneates) at a point preceding excretion into bile canaliculi. Bile is made up of many components, though two major ones are chenodeoxycholic acid and cholic acid. First, the bile acids undergo a process of conversion into acyl-CoA thioester. This occurs in two regions: in peroxisomes or endoplasmic reticulum (the latter are known as the secondary bile acids). Second, the bile acids undergo a process of conjugation which increases the detergent property, in particular in the intestine. In turn, the absorption of vitamins which are lipid soluble is faciliatated. In later steps, the deconjugation of bile acids is performed by bacteria and at this stage the bile acids are then returned to the liver to once again undergo the process of reconjugation. Familial hypercholanemia is characterized by increased bile acids in plasma. Symptoms include rickets and steatorrhea.
|
|
- (24R)-Cholest-5-ene-3-β,7-α,24...
- 24-Hydroxycholesterol
- 25-Hydroxycholesterol
- 27-Deoxy-5b-cyprinol
- 27-Hydroxycholesterol
- 3 α,7 α,24-Trihydroxy-5β-chole...
- 3 α,7 α,26-Trihydroxy-5β-chole...
- 3 β-Hydroxy-5-cholestenoate
- 3'-AMP
- 3a,7a,12a,24-Tetrahydroxy-5b-c...
- 3a,7a,12a-Trihydroxy-5b-24-oxo...
- 3a,7a,12a-Trihydroxy-5b-choles...
- 3a,7a,12a-Trihydroxy-5b-choles...
- 3a,7a-Dihydroxy-5b-cholest-24-...
- 3a,7a-Dihydroxy-5b-cholestan-2...
- 3a,7a-Dihydroxy-5b-cholestane
- 3a,7a-Dihydroxy-5b-cholestanoy...
- 3α,7α,12α-Trihydroxy-5β-choles...
- 3α,7α-Dihydroxycoprostanic aci...
- 3β,7α-Dihydroxy-5-cholestenoat...
- 5-b-Cholestane-3a ,7a ,12a-tri...
- 5b-Cyprinol sulfate
- 7 α,26-Dihydroxy-4-cholesten-3...
- 7-a,25-Dihydroxycholesterol
- 7-a,27-Dihydroxycholesterol
- 7a,12a-Dihydroxy-5b-cholestan-...
- 7a,12a-Dihydroxy-cholestene-3-...
- 7a-Hydroxy-5b-cholestan-3-one
- 7a-Hydroxy-cholestene-3-one
- 7a-Hydroxycholesterol
- 7α-Hydroxy-3-oxo-4-cholestenoa...
- Adenosine diphosphate
- Adenosine triphosphate
- CE(22:2(13Z,16Z))
- Chenodeoxycholic acid
- Chenodeoxycholic acid glycine ...
- Chenodeoxycholoyl-CoA
- Cholesterol
- Cholic acid
- Choloyl-CoA
- Coenzyme A
- Deoxycholic acid
- Deoxycholic acid glycine conju...
- FAD
- Glycine
- Glycocholic acid
- Heme
- Iron
- Lithocholic acid
- Lithocholic acid glycine conju...
- Lithocholyltaurine
- NAD
- NADH
- NADP
- NADPH
- Oxygen
- Palmitic acid
- Propionyl-CoA
- Pyrophosphate
- Taurine
- Taurochenodesoxycholic acid
- Taurocholic acid
- Taurodeoxycholic acid
- Water
- (
show all
show less
)
|
|
SMP0120698
View Pathway
|
GABA-Transaminase Deficiency
Rattus norvegicus
GABA-transaminase deficiency, also known as gamma-amino butyric acid transaminase (GABA-T) deficiency, is an extremely rare autosomal recessive inborn error of metabolism (IEM) that is caused by a defect in the ABAT gene, which codes for 4-aminobutyrate (GABA) aminotransferase. This enzyme is present in several tissues in addition to brain and is most active in liver, and it catalyzes the conversion of GABA and 2-oxoglutarate into succinic semialdehyde and L-glutamate, and when it is deficient, GABA levels in the body, specifically the cerebrospinal fluid, are elevated. GABA is a neurotransmitter found in the nervous system that inhibits neurons from firing, and also affects the development of the brain, as well as regulating muscle tone. GABA-T can also convert beta-alanine and oxoglutaric acid to L-glutamic acid and malonic semialdehyde as part of the beta-alanine metabolism pathway, and when it is mutated, leads to an accumulation of beta-alanine within the cell. GABA-T deficiency is characterized by an increase of GABA levels in the cerebrospinal fluid. Symptoms of this disorder include low muscle tone and psychomotor retardation, as well as potential epilepsy and excessive sleeping. Treatment with Flumanezil, sold as Anexate, Lanexat, Mazicon or Romazicon, a GABA-A antagonist, has been tested and may be beneficial in some cases, and potentially more effective if started at a young age. It is estimated that GABA-T deficiency affects less than 1 in 1,000,000 individuals, as only five cases have been reported in literature as of 2017.
|
|
|
|
SMP0120699
View Pathway
|
Galactosemia
Rattus norvegicus
Galactosemia (GALT Deficiency; GALT; Galactose-1-Phosphate Uridylyltransferase Deficiency) is a rare genetic disorder caused by a mutation in the GALT gene which codes for galactose-1-phosphate uridylyltransferase. A deficiency in this enzyme results in accumulation of D-galactose and galactitol in plasma and urine; bilirubin, chloride, and galactose-1-phosphate, and transaminases in serum. Symptoms, which present at birth, include jaundice, enlarged liver, anemia, weight loss, and vomiting. Treatment includes galactose-free diet, antibiotics, and vitamin K.
|
|
|
|